Mepco Home Health Agency | |
216 Boggs Lane, Richmond, Kentucky 40475 | |
(859) 623-3441 | |
Name | Mepco Home Health Agency |
---|---|
Location | 216 Boggs Lane, Richmond, Kentucky |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Home Health Aide |
Medicare ID | 187065 |
Ownership Type | Government - State/county |
Service Area Zip Codes | 40336, 40385, 40403, 40461, 40475 |
NPI Number | 1699811950 |
Organization Name | MEPCO HOME HEALTH AGENCY |
Address | 216 Boggs Lane, Richmond, KY 40475 |
Phone Number | 859-626-4509 |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
Quality Rating: |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 98.4 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 97.8 | 98.6 |
How often the home health team checked patients’ risk of falling | 99.3 | 99.6 |
How often the home health team checked patients for depression | 99.5 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 89.5 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 93.3 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 98.8 | 96.4 |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 62.3 | 79.6 |
How often patients got better at getting in and out of bed | 61 | 81.1 |
How often patients got better at bathing | 56.2 | 82.3 |
How often patients’ breathing improved | 55 | 82.8 |
How often patients’ wounds improved or healed after an operation | 93.6 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 51 | 75 |
How often home health patients had to be admitted to the hospital | 12.7 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 30.7 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 96.2 | 94 |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
The patient survey data of Mepco Home Health Agency is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 89 | 88 |
Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 86 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 94 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 76 | 78 |
News Archive
Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.
In an examination of risk factors associated with suicide in current and former military personnel observed 2001 and 2008, male sex and mental disorders were independently associated with suicide risk but not military-specific variables, findings that do not support an association between deployment or combat with suicide, according to a study in the August 7 issue of JAMA, a theme issue on violence/human rights.
TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.
Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.
› Verified 6 days ago
Mepco Home Health Agency Location: 216 Boggs Lane, Richmond, Kentucky 40475 Ratings: Phone: (859) 623-3441 |